Foley Partner George Best and Associate Shaun Snader authored an article titled “Accelerated FDA Review: Risks to Patent Term” in the July/August 2009 issue of Update Magazine.
Reprinted with permission from FDLI.
Related Insights
March 13, 2026
Innovative Technology Insights
Iran-Linked Cyberattack: What U.S. Companies Need to Know Now
Overview On March 11, 2026, independent reports confirmed that one of the largest medical device companies in the United States was the…
March 13, 2026
Blogs
What Every Multinational Should Know About…Managing the Aftermath of the Supreme Court’s Historic IEEPA Tariff Decision (Part V)
The conundrum for companies that indirectly paid the IEEPA tariffs, such as those that re-ceived price increases or outright tariff surcharges, is that the importing system is set up so that all refunds will be made by CBP directly to the importer of record. Nonetheless, compa-nies that indirectly paid the IEEPA tariffs may have contractual options, or potentially can use commercial leverage, to seek a refund of some or all of the price increases.
March 13, 2026
Tariff & International Trade Resource
What Every Multinational Should Know About…Managing the Aftermath of the Supreme Court’s IEEPA Tariff Decision (Part IV)
Importers of record need to ensure they are best positioned to secure any refunds, while also adapting to the new replacement tariffs. Therefore, on the customs side, we recommend the following steps for importers of record dealing with these issues.